The latest UK peptide medicine news — Mounjaro, Ozempic, retatrutide and NHS policy updates, tracked and explained in plain English as they happen.
A large-scale UK survey has found that households containing a Mounjaro or Wegovy user save an average of £418 per year on grocery bills compared to what they would otherwise have spent. The research adds important new context to the cost conversation around weight loss injections — a conversation that matters to millions of British…
A new experimental drug called apitegromab could help people taking Mounjaro preserve more muscle while losing weight, according to research published in Nature Medicine and reported by BBC News in June 2026. The six-month study followed 102 adults taking Mounjaro. Participants who also received apitegromab retained significantly more lean muscle mass than those receiving a…
Britain is about to approve the world’s first oral semaglutide weight loss pill. The Medicines and Healthcare products Regulatory Agency (MHRA) — the UK body that approves medicines — is expected to give the green light within days. According to the Daily Mail, reporting in June 2026, the decision is imminent and could transform access…
A weight loss injection has just posted the most impressive clinical trial results ever recorded for a medicine in this class. Retatrutide phase 3 results, published on 21 May 2026 from the TRIUMPH-1 trial, show an average body weight loss of 28.3 percent over 80 weeks on the highest dose [Eli Lilly / ClinicalTrials.gov, May…
If you have been following the world of weight loss jabs, you will know that Mounjaro (tirzepatide) was considered a game-changer. It helped people lose around 20-22% of their body weight in clinical trials. Now a new contender has arrived — and the numbers are even bigger. On 21 May 2026, Eli Lilly published topline…
A major clinical trial published on 21 May 2026 has produced the most dramatic weight loss results ever seen from a medicine. The drug is called retatrutide. Most people have not heard of it yet. But that is likely to change very quickly. [Eli Lilly / ClinicalTrials.gov, 21 May 2026] The trial is called TRIUMPH-1….